Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis
Reason given: Study early terminated due to lack of effect (did not meet primary/ secondary endpoints). This decision was not linked to safety concerns
Key facts
- Where
- Charlottesville, Chicago, Dallas, Fairfax, Hartsdale, Kansas City, Knoxville, La Mesa, Lincoln, Long Beach, Marrero, Ocoee, Phoenix, Richmond, Riverside, Sacramento, San Diego, Stamford, Sugar Land, Tampa, Tucson, Wheaton, and Winter Park, United StatesSee the 23 sites
- Phase
- Phase 2
Where in United States
- Charlottesville Medical ResearchCharlottesville, United StatesNo longer taking part
- Chicago Clinical Research InstChicago, United StatesNo longer taking part
- Metroplex Clinical ResearchDallas, United StatesNo longer taking part
- Annapolis Rheumatology LLCFairfax, United StatesNo longer taking part
- Drug Trials AmericaHartsdale, United StatesNo longer taking part
- Center for Pharmaceutical ResearchKansas City, United StatesNo longer taking part
- AMR KnoxvilleKnoxville, United StatesNo longer taking part
- Sharps Hospital GrossmontLa Mesa, United StatesNo longer taking part
- Clinical Trials ResearchLincoln, United StatesNo longer taking part
- Long Beach Clinical TrialsLong Beach, United StatesNo longer taking part
- Tandem Clinical ResearchMarrero, United StatesNo longer taking part
- Sensible HealthcareOcoee, United StatesNo longer taking part
- Elite Clinical StudiesPhoenix, United StatesNo longer taking part
- Virginia iSpine Physicians, PCRichmond, United StatesNo longer taking part
- Artemis Institute Clinical ResearchRiverside, United StatesNo longer taking part
- Northern California ResearchSacramento, United StatesNo longer taking part
- Arthemis Clinical ResearchSan Diego, United StatesNo longer taking part
- Stamford Therapeutics Consortium LLCStamford, United StatesNo longer taking part
- Pioneer Research SolutionsSugar Land, United StatesNo longer taking part
- Clinical Research of West Florida IncTampa, United StatesNo longer taking part
- Tucson Orthopedic Institute PCTucson, United StatesNo longer taking part
- The Center For Rheumatology And Bone ResearchWheaton, United StatesNo longer taking part
- Conquest ResearchWinter Park, United StatesNo longer taking part
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT04864392EU 2023-509937-37-00
- Record updated
- 2 April 2026
- Original description
This was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating intra-articular LNA043 in patients with knee osteoarthritis.Read full original descriptionShow less
A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis
This was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating intra-articular LNA043 in patients with knee osteoarthritis.
Inclusion: Males and females between 40 and 75 years of age; Body mass index (BMI) < 40 kg/m2; Diagnosis of primary tibiofemoral knee OA by standard American College of Rheumatology clinical and radiographic criteria.
Exclusion: Arthroscopy of the target knee within the 6 months prior to Screening; Hemoglobin < 8.5 g/dL (85 g/L) or platelet count < 100,000/μL; Participants with radiographic knee OA K-L grade = 4 on the non-target knee.